Lipocine (NASDAQ:LPCN) Director John Higuchi Purchases 123,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 123,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average price of $2.05 per share, with a total value of $252,150.00. Following the completion of the purchase, the director owned 163,797 shares in the company, valued at approximately $335,783.85. This trade represents a 301.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Lipocine Price Performance

LPCN opened at $1.94 on Tuesday. The firm has a fifty day moving average price of $8.10 and a 200 day moving average price of $5.78. Lipocine Inc. has a 1 year low of $1.81 and a 1 year high of $12.37. The stock has a market cap of $14.16 million, a P/E ratio of -1.15 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.26. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Hedge Funds Weigh In On Lipocine

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Lipocine during the third quarter valued at approximately $41,000. Jane Street Group LLC acquired a new position in shares of Lipocine during the fourth quarter valued at approximately $85,000. Renaissance Technologies LLC raised its holdings in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Lipocine during the fourth quarter valued at approximately $441,000. Finally, Geode Capital Management LLC raised its holdings in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares during the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on LPCN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a report on Monday. Finally, Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.